Chugai Pharmaceutical Co Ltd logo

Chugai Pharmaceutical Co Ltd

OTCPK:CHGCF (Japan)   Ordinary Shares
$ 32.43 0 (0%) 10:08 PM EST
24.46
P/B:
4.86
Market Cap:
$ 51.31B
Enterprise V:
$ 46.57B
Volume:
412.00
Avg Vol (2M):
1.61K
Also Trade In:
Volume:
412.00
Avg Vol (2M):
1.61K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for CHGCF ( Chugai Pharmaceutical Co Ltd ) from 2010 to Apr 28 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Chugai Pharmaceutical stock (CHGCF) PE ratio as of Apr 28 2024 is 24.46. More Details

Chugai Pharmaceutical Co Ltd (CHGCF) PE Ratio (TTM) Chart

To

Chugai Pharmaceutical Co Ltd (CHGCF) PE Ratio (TTM) Historical Data

Total 1215
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Chugai Pharmaceutical PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-04-28 23.8 2024-02-23 25.1
2024-04-26 23.8 2024-02-22 25.1
2024-04-25 23.8 2024-02-21 25.1
2024-04-24 23.8 2024-02-20 25.1
2024-04-23 24.4 2024-02-16 25.1
2024-04-22 24.4 2024-02-15 25.1
2024-04-19 24.4 2024-02-14 25.1
2024-04-18 24.4 2024-02-13 25.1
2024-04-17 24.4 2024-02-12 25.1
2024-04-16 24.4 2024-02-09 25.1
2024-04-15 24.4 2024-02-08 25.1
2024-04-12 24.4 2024-02-07 25.1
2024-04-11 28.7 2024-02-06 26.5
2024-04-10 28.7 2024-02-05 26.5
2024-04-09 28.7 2024-02-02 26.5
2024-04-08 28.7 2024-02-01 26.5
2024-04-05 28.7 2024-01-31 26.5
2024-04-04 28.7 2024-01-30 26.5
2024-04-03 28.7 2024-01-29 26.5
2024-04-02 28.7 2024-01-26 26.5
2024-04-01 28.7 2024-01-25 26.5
2024-03-28 28.7 2024-01-24 26.5
2024-03-27 28.0 2024-01-23 26.5
2024-03-26 28.0 2024-01-22 26.5
2024-03-25 28.0 2024-01-19 26.5
2024-03-22 28.0 2024-01-18 26.5
2024-03-21 28.0 2024-01-17 26.5
2024-03-20 29.8 2024-01-16 26.5
2024-03-19 29.8 2024-01-12 26.5
2024-03-18 29.8 2024-01-11 26.5
2024-03-15 29.8 2024-01-10 26.5
2024-03-14 29.8 2024-01-09 26.5
2024-03-13 30.4 2024-01-08 26.5
2024-03-12 31.3 2024-01-05 26.5
2024-03-11 31.3 2024-01-04 26.5
2024-03-08 31.3 2024-01-03 26.5
2024-03-07 31.3 2024-01-02 26.5
2024-03-06 28.6 2023-12-29 26.5
2024-03-05 28.6 2023-12-28 26.5
2024-03-04 28.6 2023-12-27 25.1
2024-03-01 28.6 2023-12-26 25.1
2024-02-29 28.6 2023-12-22 25.9
2024-02-28 28.6 2023-12-21 25.9
2024-02-27 25.1 2023-12-20 25.9
2024-02-26 25.1 2023-12-19 25.9

Chugai Pharmaceutical Co Ltd (CHGCF) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19 patients.